Gastrointestinal Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Multicenter Trial of ESK981 in Patients With Select Solid Tumors [Phase 2]
This document reports a Phase 2 multicenter clinical trial of ESK981 in select solid tumors. The study is currently recruiting across specif…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy [Phase 1, Phase 2]
Recruitment is ongoing for a Phase 1/2 study of the radiopharmaceutical [212Pb]VMT-alpha-NET targeting somatostatin receptors in metastatic …
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [Phase 1]
Phase 1 trial evaluating the radiopharmaceutical [212Pb]VMT-Alpha-NET across multiple somatostatin receptor–positive cancers, with recruitme…
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
A recruiting clinical study from University Health Network evaluating a non-invasive AI-based platform for patient monitoring, named NIP IT!…
-
CLINICAL_TRIALS research · 2024-08-26Clinical Trial Update: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers [Phase 1, Phase 2]
EMB-01 is being studied in a Phase 1/2 trial for advanced or metastatic gastrointestinal cancers and is currently recruiting. The sponsor is…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]
A Phase 2 clinical trial is evaluating nab-sirolimus in patients with well-differentiated neuroendocrine tumors of the gastrointestinal trac…
-
CLINICAL_TRIALS research · 2017-05-31Clinical Trial Update: Everolimus TDM to Predict Long Term Toxicity
A clinical trial evaluates whether therapeutic drug monitoring of everolimus can predict long-term toxicity in cancer patients.